Portal de Periódicos da CAPES

Plasma Assay of Matrix Metalloproteinases (MMPs) and MMP-Inhibitor Complexes in Cancer.

1994; Wiley; Volume: 732; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1994.tb24740.x

1749-6632

Stanley Zucker, Rita M. Lysik, HOSEIN M. ZARRABI, Ute M. Moll, Simon Tickle, William G. Stetler‐Stevenson, Terry Baker, Andrew Docherty,

Studies on Chitinases and Chitosanases

Annals of the New York Academy of SciencesVolume 732, Issue 1 p. 248-262 Plasma Assay of Matrix Metalloproteinases (MMPs) and MMP-Inhibitor Complexes in Cancer Potential Use in Predicting Metastasis and Monitoring Treatmenta STANLEY ZUCKER, Corresponding Author STANLEY ZUCKER Departments of Research and Medicine Veterans Affairs Medical Center Northport, New York 11768 Departments of Medicine and Pathology State University of New York at Stony Brook Stony Brook, New York 11794Address correspondence to Stanley Zucker, M.D., VA Medical Center, Mail Code 151, Northport, New York 11768.Search for more papers by this authorRITA M. LYSIK, RITA M. LYSIK Departments of Research and Medicine Veterans Affairs Medical Center Northport, New York 11768Search for more papers by this authorHOSEIN M. ZARRABI, HOSEIN M. ZARRABI Departments of Research and Medicine Veterans Affairs Medical Center Northport, New York 11768 Departments of Medicine and Pathology State University of New York at Stony Brook Stony Brook, New York 11794Search for more papers by this authorUTE MOLL, UTE MOLL Departments of Medicine and Pathology State University of New York at Stony Brook Stony Brook, New York 11794Search for more papers by this authorSIMON P. TICKLE, SIMON P. TICKLE Celltech Limited Slough SLI4EN, Berkshire, United KingdomSearch for more papers by this authorWILLIAM STETLER-STEVENSON, WILLIAM STETLER-STEVENSON Department of Pathology National Cancer Institute Bethesda, Maryland 20892Search for more papers by this authorTERRY S. BAKER, TERRY S. BAKER Celltech Limited Slough SLI4EN, Berkshire, United KingdomSearch for more papers by this authorANDREW J. P. DOCHERTY, ANDREW J. P. DOCHERTY Celltech Limited Slough SLI4EN, Berkshire, United KingdomSearch for more papers by this author STANLEY ZUCKER, Corresponding Author STANLEY ZUCKER Departments of Research and Medicine Veterans Affairs Medical Center Northport, New York 11768 Departments of Medicine and Pathology State University of New York at Stony Brook Stony Brook, New York 11794Address correspondence to Stanley Zucker, M.D., VA Medical Center, Mail Code 151, Northport, New York 11768.Search for more papers by this authorRITA M. LYSIK, RITA M. LYSIK Departments of Research and Medicine Veterans Affairs Medical Center Northport, New York 11768Search for more papers by this authorHOSEIN M. ZARRABI, HOSEIN M. ZARRABI Departments of Research and Medicine Veterans Affairs Medical Center Northport, New York 11768 Departments of Medicine and Pathology State University of New York at Stony Brook Stony Brook, New York 11794Search for more papers by this authorUTE MOLL, UTE MOLL Departments of Medicine and Pathology State University of New York at Stony Brook Stony Brook, New York 11794Search for more papers by this authorSIMON P. TICKLE, SIMON P. TICKLE Celltech Limited Slough SLI4EN, Berkshire, United KingdomSearch for more papers by this authorWILLIAM STETLER-STEVENSON, WILLIAM STETLER-STEVENSON Department of Pathology National Cancer Institute Bethesda, Maryland 20892Search for more papers by this authorTERRY S. BAKER, TERRY S. BAKER Celltech Limited Slough SLI4EN, Berkshire, United KingdomSearch for more papers by this authorANDREW J. P. DOCHERTY, ANDREW J. P. DOCHERTY Celltech Limited Slough SLI4EN, Berkshire, United KingdomSearch for more papers by this author First published: September 1994 https://doi.org/10.1111/j.1749-6632.1994.tb24740.xCitations: 27 a This research was supported by a Merit Review grant from the Department of Veterans Affairs, the Ann Shermerhorn Cancer Foundation, and Dianon Systems, Inc. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Bates, S. E. & D. L. Longo 1987. Use of serum tumor markers in cancer diagnosis and management. Semin. Oncol. 14: 102–138. 2 Liotta, L. A. 1992. Cancer cell invasion and metastasis. Sci. Am. 34–41. 3 Garbisa, S., R. Pozzatti, R. J. Muschel, U. Saffiotti, M. Ballin, R. H. Goldfarb, G. Khoury & L. A. Liotta 1987. Secretion of type IV collagenolytic protease and metastatic phenotype: Induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res. 47: 1523–1528. 4 Bernhard, E. J., R. J. Muschel & E. N. Hughes 1990. Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res. 50: 3872–3877. 5 Stearns, M. E. & M. Wang 1993. Type IV collagenase (Mr 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res. 53: 878–883. 6 Shima, I., Y. Sasaguri, J. Kusukawa, H. Yamana, H. Fujita, T. Kakegawa & M. Morimatsu 1992. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. Cancer. 70: 2747–2753. 7 Davies, B., D. W. Miles, L. C. Haperfield, M. S. Naylor, L. G. Bobrow, R. D. Rubens & F. R. Balkwill 1993. Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer. 67: 1126–1131. 8 Brown, P. D., R. E. Bloxidge, E. Anderson & A. Howell 1993. Expression of activated gelatinase in human invasive breast cancer. Clin. Exp. Metastasis. 11: 183–189. 9 Monteagudo, C., M. J. Merino, J. San-Juan, L. A. Liotta & W. G. Stetler-Stevenson 1990. Immunohistochemical distribution of type IV collagenase in normal. Benign, and malignant breast tissue. Am. J. Pathol. 136: 585–592. 10 Levy, A. T., V. Cioce, M. E. Sobel, S. Gabrisa, W. F. Grigioni, L. A. Liotta & W. G. Stetler-Stevenson 1991. Increased expression of the Mr 72,000 type IV collagenase in human adenocarcinoma. Cancer Res. 51: 439–444. 11 Basset, P., J. P. Bellocq, C. Wolf, I. Stoll, P. Hutin, J. M. Limacher, O. L. Podhajcer, M. P. Chenard, M. C. Rio & P. Chambon 1990. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 348: 699–704. 12 Poulsom, R., M. Pignatelli, W. G. Stetler-Stevenson, L. A. Liotta, P. A. Wright, T. E. Jeffrey, J. M. Longcroft, L. Rogers & G. W. H. Stamp 1992. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 141: 389–394. 13 Pyke, C., E. Ralfkiaer, K. Tryggvason & K. Dano 1993. Messenger RNA for two types of type IV collagenases is located in stromal cells in human colon cancer. Am. J. Pathol. 142: 359–365. 14 Autio-Harmainen, H., T. Karttunen, T. Hurskainen, M. Hoyhtya, A. Kauppila & K. Tryggvason 1993. Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab. Invest. 69: 312–321. 15 Clavel, C., M. Polette, M. Doco, I. Binninger & P. Birembaut 1992. Immunolocalization of matrix metalloproteinases and their inhibitor in mammary pathology. Bull. Cancer. 79: 261–270. 16 Soini, Y., T. Salo, A. Oikarinen & H. Auto-Harmainen 1993. Expression of 72 kilodalton and 92 kilodalton type IV collagenase in malignant fibrous histiocytomas and dermatofibromas. Lab. Invest. 69: 305–311. 17 Johansson, S. & B. Smedsrod 1986. Identification of a plasma gelatinase in preparations of fibronectin. J. Biol. Chem. 261: 4363–4366. 18 Vartio, T. & M. Baumann 1989. Human gelatinasesol;type IV collagenase is a regular plasma component. FEBS Lett. 155: 285–289. 19 Granstrom, L. M., G. E. Ekman, A. Malstrom, U. Ulmstem & F. Woessner 1992. Serum collagenase levels in relation to the state of the human cervix during pregnancy and labor. Am. J. Obstet. Gynecol. 167: 1284–1288. 20 Hashimoto, N., M. Ikobayashi & T. Tsuji 1988. Serum type IV collagen-degrading enzyme in hepatocellular carcinoma with metastasis. Acta Med. Okayama. 42: 1–6. 21 Ward, R. V., S. J. Atkinson, P. M. Slocombe, A. J. P. Docherty, J. J. Reynolds & G. Murphy 1991. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim. Biophys. Acta. 1079: 242–246. 22 Howard, E. W., E. C. Bullen & M. J. Banda 1991. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 266: 13064–13069. 23 Goldberg, G. I., A. Strongin, I. E. Collier, T. Genrich & B. L. Marmer 1992. Interaction of 92 kDa type IV collagenase with tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 267: 4583–4591. 24 Fridman, R., T. Fuerst, R. E. Bird, M. Hoyhtya, M. Oelkuct, S. Kraus, D. Korarek, L. A. Liotta, M. L. Berman & W. G. Stetler-Stevenson 1992. Domain structure of human 72-kDa gelatinasesol;type IV collagenase. J. Biol. Chem. 267: 15398–15405. 25 Moutsiakis, D., P. Mancuso, H. Krutzsch, W. Stetler-Stevenson & S. Zucker 1992. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect. Tissue Res. 28: 213–230. 26 Wacher, M. P., H. C. Krutzsch, L. A. Liotta & W. G. Stevenson 1990. Development of a novel substrate capture assay for the detection of a neutral metalloproteinase capable of degrading membrane (type IV) collagen. J. Immunol. Methods. 126: 239–246. 27 Bergmann, U., J. Michaelis, R. Oberhoff, V. Knauper, R. Beckmann & H. Tschesche 1989. Enzyme linked immunosorbent assay (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J. Clin. Chem. Clin. Biochem. 27: 351–359. 28 Cooksley, S., J. P. Hipkiss, S. P. Tickle, E. Holmes-Levers, A. J. P. Docherty.G. Murphy & A. D. G. Lawson 1990. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzymeinhibitor complexes. Matrix. 10: 285–291. 29 Zucker, S., R. M. Lysik, M. H. Zarrabi & U. Moll 1993. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53: 140–146. 30 Zucker, S., R. M. Lysik, M. Gurfinkel, M. H. Zarrabi, W. G. Stetler-Stevenson, L. A. Liotta, H. Birkedal-Hansen & W. Mann 1992. Immunoassay of type IV collagenasesol;gelatinase (MMP-2) in human plasma. J. Immunol. Methods. 148: 189–198. 31 Clark, I. M., J. K. Wright, T. E. Cawston & B. L. Hazleman 1992. Polyclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure TIMP-collagenase complex. Matrix. 12: 108–115. 32 Kieldsen, L., O. W. Bjerrun, D. Hovgaard, A. H. Johnsen, M. Sehested & N. Borregaard 1992. A marker for circulating neutrophils. Purification and quantification by enzyme linked immunosorbent assay. Eur. J. Haematol. 49: 180–191. 33 Zucker, S., R. M. Lysik, M. H. Zarrabi, W. Stetler-Stevenson, L. A. Liotta, H. Birkedal-Hansen, W. Mann & M. Furie 1992. Type IV collagenasesol;gelatinase (MMP2) is not increased in plasma of patients with cancer. Cancer Epidemiol. Biomarkers Prevention. 1: 475–479. 34 Garbisa, S., G. Scagliotti, L. Masiero, C. DiFrancesco, C. Caenazzo, M. Onisto, M. Micela, W. G. Stetler-Stevenson & L. A. Liotta 1992. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 52: 4548–4549. 35 Nakajima, M., D. R. Welch, D. M. Wynn, T. Tsuruo & G. L. Nicholson 1993. Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762 NF mammary adenocarcinoma. Cancer Res. 5802–5807. 36 Zucker, S., R. M. Lysik, M. H. Zarrabi, R. A. Greenwald, B. Gruber, S. P. Tickle, T. S. Baker & A. J. P. Docherty 1994. Elevated plasma stromelysin levels in arthritis. J. Rheumatol. In press. 37 Reponen, P., C. Sahlberg, P. Huhtala, T. Hurskainen, I. Theslett & K. Tryggvason 1992. Molecular cloning of murine 72-kDa type IV collagenase and its expression during mouse development. J. Biol. Chem. 267: 7856–7862. 38 Mackay, A. R., M. Ballin, M. D. Pelina, A. R. Farina, A. M. Nason, J. L. Hartzler & U. P. Thorgeirsson 1992. Effect of phorbol ester and cytokines on matrix metallopro-teinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis. 12: 168–184. 39 Moscatelli, D. & D. B. Rifkin 1988. Membrane and matrix localization of proteinases: A common theme in tumor invasion and angiogenesis. Biochim. Biophys. Acta. 948: 67–84. 40 Zucker, S., R. M. Lysik, M. H. Zarrabi, J. J. Fiore & D. K. Strickland 1991. Proteinase-alpha2 macroglobulin complexes are not increased in plasma of patients with cancer. Int. J. Cancer. 48: 399–403. 41 Zucker, S., P. Mancuso, B. DiMassimo, R. M. Lysik, C. Conner & C.-L. Wu 1994. Comparison of techniques for measurement of gelatinasesol;type IV collagenases: Enzyme-linked immunoassays versus substrate degradation assays. Clin. Exp. Metastasis. In press. 42 Okada, Y., H. Nagase & E. D. Harris 1986. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J. Biol. Chem. 261: 14245–14255. Citing Literature Volume732, Issue1Inhibition of Matrix Metalloproteinases: Therapeutic PotentialSeptember 1994Pages 248-262 ReferencesRelatedInformation